ESMO 2016

October 7th-11th

Copenhagen Denmark


ESMO 2016 Congress, 09.10.2016, 09:30 - 10:30, Brussels

728PD - Impact of AR-V7 protein localization in the prediction of therapeutic benefit of taxanes over androgen receptor signaling inhibitors (ARSi) in metastatic castration resistant prostate cancer (mCRPC)


730PD - Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifer in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 trial


ESMO 2016 Congress, 10.10.2016, 13:00 - 14:00, Hall E

75P - PD-L1 expression on circulating CD45(-) cells is an independent prognostic factor for overall survival (OS) in patients (Pts) across all stages of treatment-naïve lung cancer in a prospective, multicenter study


ESMO 2016 Congress, 09.10.2016, 13:00 - 14:00, Hall E

766TiP - CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent